Healios K.K. to Showcase Innovative Biotech Advances
Healios K.K. Unveils Presentation Details for Upcoming Conference
Healios K.K. is excited to announce that Richard Kincaid, the Chief Financial Officer, will present at a prominent industry event, showcasing the company's advancements in biotechnology. This presentation provides an opportunity for stakeholders and interested parties to gain insight into Healios' innovative projects and future plans.
Event Information
Date and Time
The presentation is scheduled for Thursday, June 5, ensuring participation from a diverse audience passionate about healthcare innovation.
How to Access the Webcast
Participants can access the event through a live and recorded webcast that will be available on Jefferies’ website. This will allow attendees to engage with the material and remain informed even after the conference concludes, with replay access granted for 60 days.
Schedule One-on-One Meetings
For those interested in deeper engagement and discussion, Healios invites potential investors and partners to schedule one-on-one meetings. Please contact your Jefferies representative to arrange a meeting that suits your schedule.
About Healios K.K.
Healios K.K. stands at the forefront of clinical stage biotechnology in Japan, leveraging the groundbreaking potential of stem cells for regenerative medicine. The company has pioneered numerous advancements in the field and holds unique global platforms that utilize both somatic stem cells and induced pluripotent stem (iPS) cells. Among its notable projects is invimestrocel (HLCM051), an innovative cell product derived from the bone marrow of healthy adult donors. Healios is committed to advancing this product for various critical health conditions, including ischemic stroke and acute respiratory distress syndrome (ARDS).
Notably, Healios is nearing conditional approval in Japan for invimestrocel's use in treating ARDS and is preparing for commercial launch following the approval process.
Established in 2011, Healios has been listed on the Tokyo Stock Exchange since 2015, represented by the ticker JPX:4593.T, marking its commitment to transparency and growth as it navigates the complexities of the biotechnology market.
Contact Information
U.S. Investor Relations:
Lisa M. Wilson
T: 212-452-2793
E: lwilson@insitecony.com
For inquiries related to investor relations, Richard Kincaid, Executive Officer, is reachable via email at ir@healios.jp.
Frequently Asked Questions
What is Healios K.K. known for?
Healios K.K. is recognized for its pioneering role in developing innovative regenerative medicines utilizing stem cell technology.
When is the 2025 Jefferies Global Healthcare Conference?
The conference presentation will occur on June 5, with Richard Kincaid scheduled to speak at 2:35 PM EST.
How can I access the conference webcast?
The webcast will be available live and archived on Jefferies' website for 60 days post-conference.
How does Healios plan to expand its market reach?
Healios aims to advance its products globally, particularly focusing on gaining approval for treatments in critical health areas like ARDS.
What are somatic stem cells?
Somatic stem cells are undifferentiated cells that can develop into various cell types and are crucial for regenerative treatments.
About The Author
Contact Thomas Cooper privately here. Or send an email with ATTN: Thomas Cooper as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.